Apolipoprotein L2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-06978
Key Product Details
Species Reactivity
Human
Applications
Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence C-TKIHEMLQPGQD corresponding to C-Terminus according to NP_112092.1, NP_663612.1.
Epitope
C Terminus
Specificity
Both reported isoforms represent identical proteins (NP_112092.1; NP_663612.1).
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Apolipoprotein L2 Antibody
Western Blot: Apolipoprotein L2 Antibody [NBP1-06978]
Western Blot: Apolipoprotein L2 Antibody [NBP1-06978] - NBP1-06978 (0.03ug/ml) staining of Human Frontal Cortex lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.Applications for Apolipoprotein L2 Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:64000
Western Blot
0.03 - 0.1 ug/ml
Application Notes
WB: Approx. 37.1 kDa band observed in human brain (frontal cortex) lysates (calculated MW of 38 kDa band according to NP_112092.1; NP_663612.1).
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Apolipoprotein L2
Alternate Names
APOL3, ApoL-II, apolipoprotein L, 2, apolipoprotein L2, Apolipoprotein L-II
Entrez Gene IDs
23780 (Human)
Gene Symbol
APOL2
UniProt
Additional Apolipoprotein L2 Products
Product Documents for Apolipoprotein L2 Antibody
Product Specific Notices for Apolipoprotein L2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...